Eli Lilly under pressure as Alzheimer's application delayed
The treatment has hit a stumbling block related to Medicare coverage.
by marketwire, translated by catherine brett
Shares in Eli Lilly dropped by 1.7 percent in value on Thursday, after the leadership team at the US-based pharmaceutical company revealed that their plans to apply for marketing authorization for its Alzheimer’s treatment have been delayed.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly's Trulicity beats growth expectations
For subscribers
Eli Lilly prepares for FDA rejection of eczema treatment
For subscribers
